Insider Selling: United Therapeutics Corporation (UTHR) CEO Sells 1,269 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,269 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $118.04, for a total value of $149,792.76. Following the sale, the chief executive officer now directly owns 1,409 shares of the company’s stock, valued at approximately $166,318.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at $121.00 on Monday. The firm has a market capitalization of $5,228.54, a PE ratio of 10.67 and a beta of 1.38. United Therapeutics Corporation has a one year low of $112.01 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The firm had revenue of $445.50 million for the quarter, compared to the consensus estimate of $426.43 million. During the same quarter in the prior year, the business earned $4.23 earnings per share. The company’s revenue was up 9.1% compared to the same quarter last year. analysts expect that United Therapeutics Corporation will post 11.92 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: United Therapeutics Corporation (UTHR) CEO Sells 1,269 Shares of Stock” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/11/13/martine-a-rothblatt-sells-1269-shares-of-united-therapeutics-corporation-uthr-stock.html.

A number of hedge funds have recently modified their holdings of UTHR. Wells Fargo & Company MN raised its holdings in shares of United Therapeutics Corporation by 144.0% during the second quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock valued at $94,785,000 after acquiring an additional 431,210 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of United Therapeutics Corporation by 308.6% during the second quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock valued at $64,930,000 after acquiring an additional 378,002 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of United Therapeutics Corporation by 65.5% during the second quarter. Renaissance Technologies LLC now owns 837,600 shares of the biotechnology company’s stock valued at $108,662,000 after acquiring an additional 331,400 shares during the last quarter. Schroder Investment Management Group raised its holdings in shares of United Therapeutics Corporation by 42.8% during the second quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock valued at $143,359,000 after acquiring an additional 327,360 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of United Therapeutics Corporation by 58.0% during the second quarter. Dimensional Fund Advisors LP now owns 726,760 shares of the biotechnology company’s stock valued at $94,286,000 after acquiring an additional 266,790 shares during the last quarter.

UTHR has been the subject of a number of recent analyst reports. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. BidaskClub cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. ValuEngine raised United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Zacks Investment Research raised United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a research report on Monday, October 9th. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $95.00 price objective on shares of United Therapeutics Corporation in a research note on Thursday, October 26th. Five analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. United Therapeutics Corporation has a consensus rating of “Hold” and a consensus price target of $132.82.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply